NASDAQ:MGX | Cash Flow Statement | Metagenomi Therapeutics, Inc.

Complete source-backed cash-flow history.

Available history
2023-03-31 to 2026-06-30
Data captured

Historical Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2026-06-30-$27.48M
2026-03-31-$23.06M-$21.18M$25,000.00$3.99M-$27,000.00
2025-12-31-$22.53M-$23.55M$85,000.00$32.37M$74,000.00
2025-09-30-$20.39M
2025-06-30-$19.91M
2025-03-31-$25.04M-$22.84M$288,000.00$24.73M-$77,000.00
2024-12-31-$23.4M-$26.28M$334,000.00$28.55M$0.00
2024-09-30-$18.77M
2024-06-30-$10.74M
2024-03-31-$25.15M-$29.85M$915,000.00-$94.73M$86.54M
2023-12-31-$19.29M-$20.59M$1.74M$60.63M-$1.33M
2023-09-30-$19.82M
2023-06-30-$13.01M
2023-03-31-$16.13M-$21M$2.67M-$72.07M$4.3M

Annual Cash Flow Statement

DateNet incomeDepreciation and amortizationOperating cash flowCapital expenditureInvesting cash flowShare repurchasesDividends paidFinancing cash flow
2025-12-31-$87.87M-$88.89M$574,000.00$103.53M-$356,000.00
2024-12-31-$78.06M-$109.07M$3.11M-$88.16M$84.01M
2023-12-31-$68.26M-$91.41M$9.81M$45.73M$1.01M